Adial Pharmaceuticals to Showcase Innovations at Conference
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a leading company in the biopharmaceutical industry focused on addiction therapies, is preparing to present at the H.C. Wainwright 26th Annual Global Investment Conference. This important event is scheduled for September 9-11, 2024, at a prestigious venue in New York City.
Details of the CEO's Presentation
Cary Claiborne, the CEO of Adial Pharmaceuticals, will lead the presentation, which aims to showcase the company's groundbreaking treatment options for addiction and related disorders. Registered attendees will have the chance to view the presentation on-demand via the conference platform starting September 9, 2024, at 7:00 AM Eastern Time.
Adial's Dedication to Addiction Treatment
Adial Pharmaceuticals is well-known for its commitment to developing effective treatments for addiction, employing scientific rigor and innovative approaches. The company’s flagship investigational product, AD04, is making significant strides in this field. This medication acts as a serotonin-3 receptor antagonist specifically designed to treat Alcohol Use Disorder (AUD) in heavy drinkers. The encouraging results from the ONWARD™ pivotal Phase 3 clinical trial have demonstrated its effectiveness in reducing heavy drinking, offering hope to many patients.
Analyzing Results and Future Opportunities
The ONWARD study not only showcased AD04's capacity to reduce heavy drinking but also confirmed a favorable safety profile. Furthermore, AD04 is thought to have potential applications for treating other addictions, such as Opioid Use Disorder, gambling addiction, and obesity, highlighting Adial’s ambition to broaden its influence in the addiction treatment arena.
Engaging with Investors
During the conference, Adial’s management team will actively participate in one-on-one meetings with investors, aiming to build meaningful connections within the investment community. Interested individuals who wish to arrange a meeting are encouraged to contact Adial's communications team directly.
Contact Information for Investor Relations
For any inquiries regarding meetings or additional information, potential investors can reach out to Adial’s investor relations via email. Additionally, more comprehensive details about Adial Pharmaceuticals and their innovative treatment options can be found on their official website.
Frequently Asked Questions
What is Adial Pharmaceuticals focused on?
Adial Pharmaceuticals is dedicated to developing therapies for addiction treatment and prevention.
When will Adial present at the conference?
Adial's presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time.
What is the significance of AD04?
AD04 is an investigational treatment aimed at addressing Alcohol Use Disorder and shows potential for treating other addictions.
How can investors connect with Adial during the conference?
Investors can schedule one-on-one meetings with management by reaching out to the company’s investor relations team.
Where can I find more information about the company?
Additional information about Adial Pharmaceuticals can be found on their official website.
